Clinical Trials Browser

Phase 2 × NIH × eribulin × Clear all

NCT03237780 2026-03-18

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT02097238 2020-05-19

Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

Phase 2 Completed

19 enrolled 12 charts

Osteosarcoma

NCT02178241 2019-12-16

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

Phase 2 Completed

26 enrolled 9 charts

Ureteral Neoplasms, Urethral Neoplasms

NCT00334893 2017-11-29

Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Phase 2 Completed

74 enrolled 7 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00383760 2017-10-20

Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients

Phase 2 Completed

15 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00337129 2015-08-25

S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Phase 2 Completed

42 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00400829 2015-01-07

E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

66 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung

NCT00337077 2014-06-23

Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2 Completed

121 enrolled 8 charts

Prostatic Neoplasms